Clinical Trial Update: Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) [Phase 1]

View source ↗

Summary

Phase 1 trial for MK-8808 in follicular lymphoma was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• MK-8808

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Follicular Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2015-11-25